4G
4G8.F Guerbet SA
- Market cap
- EUR 79.9M
- P/E
- -
- P/B
- 0.32x
- ROE
- -40.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 4G8.F undervalued?
Graham numberThe Graham number of Guerbet SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Guerbet SA fundamental analysis
No fundamental analysis for Guerbet SA yet.
Guerbet SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Guerbet SA
Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconnected solution; and Artirem, a gadoteric acid. The company also provides OptiStar…
Full company profileGuerbet SA financial statements
Guerbet SA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 776M | 809M | 795M | 819M | 717M | 736M | 769M | 796M | 851M | 799M |
| Gross Profit | 590M | 619M | 602M | 617M | 525M | 517M | 558M | 589M | 627M | 566M |
| Operating Income | 56.0M | 81.0M | 66.1M | 52.9M | 41.3M | 39.4M | 42.9M | 39.2M | 48.8M | 8.09M |
| EBITDA | - | 116M | 124M | 117M | 86.2M | 92.6M | 99.3M | 103M | 113M | 72.6M |
| Net Income | 28.9M | 46.2M | 46.8M | 37.3M | 17.7M | 32.6M | -41.1M | 23.9M | 16.1M | -108M |
| EPS | - | 3.68 | 3.74 | 2.97 | 1.41 | 2.58 | -3.26 | 1.90 | 1.28 | -8.59 |
| Balance Sheet | ||||||||||
| Total Assets | 1.03B | 954M | 1.08B | 1.01B | 946M | 1.00B | 940M | 1.03B | 1.04B | 930M |
| Total Liabilities | 713M | 611M | 714M | 620M | 581M | 596M | 560M | 647M | 646M | 670M |
| Shareholders' Equity | 315M | 342M | 367M | 389M | 364M | 405M | 380M | 378M | 394M | 267M |
| Cash & Short-term Investments | 96.5M | 75.4M | 103M | 78.4M | 96.7M | 116M | 41.7M | 51.3M | 50.2M | 116M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 38.7M | 56.1M | 76.9M | 131M | 120M | 116M | 30.4M | 27.4M | 81.2M | 81.1M |
| Capital Expenditure | 49.8M | 26.4M | 32.7M | 38.9M | 39.8M | 37.5M | 50.5M | 54.0M | 57.0M | 36.6M |
| Free Cash Flow | - | 9.56M | 32.8M | 71.8M | 60.8M | 67.0M | -20.1M | -26.6M | 24.2M | 44.5M |
| Ratios | ||||||||||
| ROE | 9.2% | 13.5% | 12.8% | 9.6% | 4.9% | 8.1% | -10.8% | 6.3% | 4.1% | -40.6% |
| ROA | 2.8% | 4.8% | 4.3% | 3.7% | 1.9% | 3.3% | -4.4% | 2.3% | 1.6% | -11.6% |
| Net Profit Margin | 3.7% | 5.7% | 5.9% | 4.6% | 2.5% | 4.4% | -5.3% | 3.0% | 1.9% | -13.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Guerbet SA dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 1, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | EUR 6.31M | 0.50 | 39.2% |
| 2023 | EUR 6.31M | 0.50 | 26.4% |
| 2022 | EUR 10.7M | 0.85 | - |
| 2021 | EUR 8.81M | 0.70 | 27.0% |
| 2020 | EUR 8.83M | 0.70 | 49.8% |
| 2019 | EUR 10.7M | 0.85 | 28.6% |
| 2018 | EUR 10.7M | 0.85 | 22.9% |
| 2017 | EUR 10.7M | 0.86 | 23.2% |
| 2016 | EUR 8.01M | - | 27.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 4:1 on Jan 23, 2014.
Who owns Guerbet SA
- Insiders 63.21%
- Institutions 3.91%
- Public & others 32.88%
- Shares outstanding 12.6M
- Free float 5.05M
Guerbet SA company profile
- Company name
- Guerbet SA
- Ticker
- 4G8.F
- ISIN
- FR0000032526
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 2,653
- Fiscal year end
- December
- Address
- 15 rue des Vanesses, Villepinte, France, 93420
- Phone
- 33 1 45 91 50 00
- Website
- guerbet.com
About Guerbet SA
Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconnected solution; and Artirem, a gadoteric acid. The company also provides OptiStar Elite, a dual head contrast delivery system with an ultrasonic motor; Ready-Box, a contrast media warmer; MRI accessories and consumables for diagnostic imaging; OptiProtect 3S, a suite of services and support solution; Conray/Cysto-Conray, an iothalamate meglumine injection contrast agent for CT; Micropaque/Microtrast, a barium sulfate contrast agent for CT; Optiray, an ioversol contrast agent for CT and Cath lab; Telebrix Gastro, a meglumine ioxitalamate contrast agent for CT; and Xenetix/ScanBag by Xenetix, an Iobitridol contrast agent for CT and Cath lab. In addition, it offers OptiBolus, which allows for a uniform vascular enhancement throughout the procedure; OptiOne, a single head injector; OptiVantage Multi-use, an optimal power injector for X-ray procedures; OptiVantage, a dual-head CT contrast delivery injector; Illumena Néo, a multi-mode contrast delivery injector; Lipiodol Ultra Fluid, an iodinated ethyl ester of fatty acids of poppy seed oil; Qitexio, a range of lipiodol resistant medical devices consisting of medical syringes and a stopcock; Lipiodol Ultra Fluid for use in interventional radiology and women's health; and Patent Blue V, a pharmaceutical drug for breast cancer. The company was founded in 1901 and is headquartered in Villepinte, France.
Guerbet SA management
10- Mr. Jerome EstampesChief Financial Officer · born 1968
- Mr. Philippe BourrinetEVP Development of Medical & Regulatory Affairs, Deputy CEO and Chief Pharmaceutical Officer · born 1968
- Mr. Karim BoussebaaChief Executive Officer
- Ms. Charlotte BamiereChief Legal & Compliance Officer
- Christine AllardExecutive VP Communications, Public Affairs & CSR
- Eva OhlssonChief People Officer
- Mr. Francois NicolasChief Strategy Officer & Executive VP Innovation and Chief Digital Officer · born 1971
- Ms. Valérie BrissartExecutive VP Marketing of Diagnostic Imaging
- Mr. François ConvenantExecutive of VP Interventional Radiology and Global VP of Commercial & Interventional Imaging
- Eric KummerExecutive VP of Operations